As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer.
Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-August 2019.